166388-57-4

166388-57-4 structure

Name: Azido-PEG2-C2-amine
Chemical Name: 2-[2-(2-azidoethoxy)ethoxy]ethanamine
CAS Number: 166388-57-4
Molecular Formula: C₆H₁₄N₄O₂
Molecular Weight: 174.20100
Catalog: Chemical reagent Organic reagent Azide
Create Date: 2019-02-04 12:06:26
Modify Date: 2026-08-15 13:06:26
Azido-PEG2-C2-amine (N3-PEG2-CH2CH2NH2) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. Azido-PEG2-C2-amine is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[2].

Name	2-[2-(2-azidoethoxy)ethoxy]ethanamine
Synonyms	N3-PEG2-CH2CH2NH2 Azido-PEG2-NH2 2-[2-(2-azidoethoxy)-ethoxy]-ethylamine Azido-PEG2-CH2CH2NH2 N3-PEG2-CH2CH2NH2/Ethanamine, 2-[2-(2-azidoethoxy)ethoxy] Azido-PEG2-Amine 2-[2-(2-Azido-ethoxy)-ethoxy]-ethylamine 2-(2-(2-azidoethoxy)exthoxy)ethanamine Amino-PEG2-Azide Amino-PEG2-azide,NH2-PEG2-N3 2-azidoethyloxyethyloxyethylamine 2-[2-(2-Azidoethoxy)ethoxy]ethanamine N3-PEG2-NH2 Ethanamine, 2-[2-(2-azidoethoxy)ethoxy] Azide-PEG3-Amine Azido-PEG2-CH2CH2-Amine 1-AMINO-8-AZIDO-3,5-DIOXAOCTANE H2N-C2-PEG2-N3 2-(2-(2-azidoethoxy)ethoxy)ethanamine 1-(2-AMINOETHOXY)-2-(2-AZIDOETHOXY)ETHANE

Description	Azido-PEG2-C2-amine (N3-PEG2-CH2CH2NH2) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. Azido-PEG2-C2-amine is also a non-cleavable 2 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Antibody-drug Conjugate >> ADC Linker Signaling Pathways >> PROTAC >> PROTAC Linker
Target	PEGs Non-cleavable
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[2].
References	[1]. Su S, et al. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. J Med Chem. 2019 Aug 22;62(16):7575-7582. [2]. Tominari, Yusuk , et al. Heterocyclic compound. WO2020027225A1.

59559-06-7

~99%

166388-57-4

929-59-9

~76%

166388-57-4

Literature: Li, Ying; Schaffer, Paul; Perrin, David M. Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 23 p. 6313 - 6316

950683-55-3

~57%

166388-57-4

Literature: Lu, Yan; Gervay-Hague, Jacquelyn Carbohydrate Research, 2007 , vol. 342, # 12-13 p. 1636 - 1650

112-26-5

166388-57-4

Literature: Bioorganic and Medicinal Chemistry Letters, , vol. 17, # 6 p. 1499 - 1503

1334782-19-2

166388-57-4

Literature: Zheng, Hong; Wang, Fang; Wang, Qin; Gao, Jianmin Journal of the American Chemical Society, 2011 , vol. 133, # 39 p. 15280 - 15283

153086-78-3

166388-57-4

Literature: Carbohydrate Research, , vol. 342, # 12-13 p. 1636 - 1650

139115-92-7

166388-57-4

Literature: Journal of the American Chemical Society, , vol. 133, # 39 p. 15280 - 15283

112-27-6

166388-57-4

Literature: Journal of the American Chemical Society, , vol. 134, # 45 p. 18809 - 18815

19249-03-7

166388-57-4

Literature: Journal of the American Chemical Society, , vol. 134, # 45 p. 18809 - 18815